Double-Blind, Placebo Controlled Pilot Study of Octanoic Acid in Essential Tremor
NCT00848172 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 29
Last updated 2012-12-27
Summary
Background:
* Essential tremor (ET) is a neurological disorder characterized by uncontrollable shaking. Several medications are used to treat ET; however, they are often only partly effective and can have side effects.
* Research studies have shown that octanol, a food additive similar to alcohol, can improve tremor in animals. Octanol is less likely to make people drunk than alcohol. Two earlier NIH studies found that one form of octanol, called 1-octanol, did improve tremor in some people and had few side effects.
* In the body, 1-octanol is converted to octanoic acid. Researchers are interested in finding out whether octanoic acid can help people with ET.
Objectives:
* To find out if octanoic acid can improve hand tremor in people with essential tremor.
* To measure levels of octanoic acid in the blood after it is taken.
Eligibility:
* Patients 21 years of age and older with ET, who are willing to abstain from alcohol, caffeine, and all medications as required by the study and who are willing and able to fast for up to 12 hours at a time.
* Participants may not be of Asian or Native American ancestry because of genetic susceptibilities to the intoxicating effects of the study drug.
Design:
* This study requires a 3-day hospital admission as well as two outpatient visits.
* Visit 1 (outpatient): Screening visit and blood alcohol level test
* Medical history, physical and neurological examination, a blood test, and an electrocardiogram to measure heart function. Women who are able to get pregnant will have a urine pregnancy test.
* Patients will consume 1.5 ounces of alcohol per drink (up to three drinks at least 30 minutes apart), and be tested to evaluate how the tremor responds. Researchers will draw blood to measure blood alcohol level about 1 hour after the first drink and closely monitor patients for signs of intoxication.
* Inpatient examination
* Preparation: Researchers will prepare a schedule to stop any tremor medications that patients might be on. Patients may not drink alcohol or eat or drink anything with caffeine, including chocolate, for at least 2 days before admission.
* Day 1: Vital signs, blood (and urine pregnancy) tests, and electrocardiogram. Patients will be asked to wear a tremor monitor, similar to a wristwatch. Patients will also have IV lines inserted for blood draws.
* Days 2 and 3: Randomized study medication (octanoic acid on one day, placebo on the other day). Patients will fast before taking the drug, but will be allowed to eat and drink after the tests are completed (around noon).
* Blood will be drawn before taking the study drug and again (a total of nine times) after taking the drug.
* Tremor will be measured during the study, before and after taking the drug.
* Visit 2 (outpatient): 4 to 7 days after discharge
* Blood test and an electrocardiogram, and a series of questionnaires regarding the study.
Conditions
Interventions
- DRUG
-
Octanoic Acid
4mg/kg
- DRUG
-
identical capsules
Sponsors & Collaborators
-
National Institute of Neurological Disorders and Stroke (NINDS)
lead NIH
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- QUADRUPLE
- Model
- CROSSOVER
Eligibility
- Min Age
- 21 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2009-02-28
- Primary Completion
- 2010-11-30
- Completion
- 2010-11-30
Countries
- United States
Study Locations
More Related Trials
-
Novel Therapies for Essential Tremor
NCT00018564 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase 2 RCT Study of CX-8998 for Essential Tremor
NCT03101241 ·Status: COMPLETED ·Phase: PHASE2
-
A Pilot Efficacy and Safety Study of ST101 in Essential Tremor
NCT01332695 ·Status: COMPLETED ·Phase: PHASE2
-
Acamprosate and Methazolamide for Essential Tremor
NCT06312800 ·Status: WITHDRAWN ·Phase: PHASE2
-
Study of the Oral Treatment MTR-601 in Cervical Dystonia
NCT06830642 ·Status: SUSPENDED ·Phase: PHASE2
-
A Clinical Trial of 2 Doses of PRAX-944 in Participants With Essential Tremor
NCT05021991 ·Status: COMPLETED ·Phase: PHASE2
-
A Clinical Study to Evaluate CAD-1883 in Essential Tremor
NCT03688685 ·Status: COMPLETED ·Phase: PHASE2
-
Multiple-dose,Double-blind,Placebo-controlled Study of Sodium Oxybate in Patients With Essential Tremor
NCT00598078 ·Status: COMPLETED ·Phase: PHASE2
-
A Clinical Trial of PRAX-944 in Participants With Essential Tremor
NCT05021978 ·Status: COMPLETED ·Phase: PHASE2
-
Acute Unilateral Vestibulopathy and Corticosteroid Treatment
NCT02912182 ·Status: TERMINATED ·Phase: PHASE4
-
Efficacy, Tolerability, and Pharmacokinetics of Multiple Doses of Oral TAK-831 in Adults With Friedreich Ataxia
NCT03214588 ·Status: COMPLETED ·Phase: PHASE2
-
A Proof of Concept Study of the Effectiveness of Carisbamate in the Treatment of Essential Tremor
NCT00524056 ·Status: COMPLETED ·Phase: PHASE2
-
Trial of Cannabis for Essential Tremor
NCT03805750 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Phase III Randomized, Double-Blind, Placebo-Controlled Study of Dichlorphenamide for Periodic Paralyses and Associated Sodium Channel Disorders
NCT00004802 ·Status: COMPLETED ·Phase: PHASE3
-
Upper Limb Tremor Reduction in Essential Tremor Patients
NCT06343285 ·Status: COMPLETED ·Phase: NA
-
Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS
NCT00021697 ·Status: COMPLETED ·Phase: PHASE3
-
Zonisamide in the Treatment of Essential Tremor
NCT00616343 ·Status: TERMINATED ·Phase: NA
-
A Study to Evaluate the Efficacy, Safety, and Tolerability of SAGE-324 in Participants With Essential Tremor
NCT04305275 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy Study of A0001 in Subjects With Friedreich's Ataxia
NCT01035671 ·Status: COMPLETED ·Phase: PHASE2
-
NF-κB Inhibition in Amyotrophic Lateral Sclerosis
NCT05031351 ·Status: UNKNOWN ·Phase: PHASE2
-
Efficacy and Safety of Nitrazine in the Treatment of ALS
NCT04950647 ·Status: UNKNOWN ·Phase: PHASE2
-
Study to Evaluate Multiple Ascending Dose and Multi-Dose of DT-216 in Adult Patients With Friedreich Ataxia
NCT05573698 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Investigate the Safety and Efficacy of Lithium in Volunteers With Amyotrophic Lateral Sclerosis (ALS)
NCT00818389 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
Dose Titration Study to Test Safety and Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
NCT01486849 ·Status: COMPLETED ·Phase: PHASE2
-
Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease
NCT03082755 ·Status: RECRUITING ·Phase: PHASE4